Chemotherapy-Induced Neutropenia Treatment Market 2022-2028

Description

List of Tables

Global Chemotherapy-Induced Neutropenia Treatment Market Size, Share & Trends Analysis Report by Therapy Type (Antibiotic Therapy, Colony-Stimulating Factor Therapy, Granulocyte Transfusion, Splenectomy Transfusion, and Others), and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) Forecast 2022-2028

The global chemotherapy-induced neutropenia treatment market is anticipated to grow at a significant CAGR during the forecast period. Chemotherapy-induced neutropenia is a cancer-related side effect that directly affects the bone marrow. Patients who have developed neutropenia as a result of chemotherapy must be admitted to the hospital. Furthermore, as an anti-infective medication is employed, the cost of treatment grows. The key driver of market growth is the growing use of chemotherapy for cancer treatment, as well as the rising prevalence of cancer around the world. According to the National Cancer Institute (NCI), there will be 1,806,590 new cancer cases diagnosed in the United States in 2020, with a 606,520 deaths rate. The most common cancers include breast cancer, lung and bronchus cancer, and leukemia, among others. In 2020, prostate, lung, and colorectal cancers will account for around 43% of all new cancer diagnoses in men, while breast, lung, and colorectal cancers will account for almost 50% of all new cancer diagnoses in women.

The global chemotherapy-induced neutropenia treatment market is segmented based on the therapy type and distribution channel. Based on the type, the market is sub-segmented into antibiotic therapy, colony-stimulating factor therapy, granulocyte transfusion, splenectomy procedure, and others. Based on the distribution channel, the global chemotherapy-induced neutropenia treatment market is divided into hospital pharmacy, retail pharmacy, and online pharmacy. Among these, colony-stimulating factor therapy is expected to propel the growth of the market, due to its ability to help bone marrow produce more white blood cells.

The global chemotherapy-induced neutropenia treatment market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). The market can be analyzed for a particular region or country level as per the requirement. Among the regions, the Asia-Pacific region in the global chemotherapy-Induced neutropenia treatment market is expected to hold a prominent market share due to the presence of several key market players. For Instance, in December 2021, Lupin Pharmaceuticals, Inc. signed an agreement with Biomm SA for the distribution of Pegfilgrastim in Brazil. Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy. Additionally, the surge in government policies is now allowing many players to come into the market with their innovative products.

The major companies serving the global chemotherapy-induced neutropenia treatment market include Amgen, Inc., Sanofi S.A., Novartis International AG, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2019, GSK completed the acquisition of TESARO, an oncology-focused biopharmaceutical company. It will strengthen GSK's pharmaceutical business, accelerating the build of GSK's pipeline and commercial capability in the oncology

Research Methodology

The market study of the global chemotherapy-induced neutropenia treatment market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

Financial reports of companies involved in the market.
Whitepapers, research papers, and news blogs.
Company websites and their product catalogue.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Solar Carport Charging Station Market Research and Analysis by Therapy Type.

2. Global Solar Carport Charging Station Market Research and Analysis by Distribution Channel.

The Report Covers:

Comprehensive Research Methodology of the global chemotherapy-induced neutropenia treatment market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global chemotherapy-induced neutropenia treatment market.
Insights about market determinants that are stimulating the global chemotherapy-induced neutropenia treatment market.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: OMR2025712

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the Global Chemotherapy-Induced Neutropenia Treatment Market
Recovery Scenario of Global Chemotherapy-Induced Neutropenia Treatment Market
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Amgen Inc.
- 3.1.1. Overview
- 3.1.2. Financial Analysis
- 3.1.3. SWOT Analysis
- 3.1.4. Recent Developments
3.2. BeyondSpring Inc.
- 3.2.1. Overview
- 3.2.2. Financial Analysis
- 3.2.3. SWOT Analysis
- 3.2.4. Recent Developments
3.3. Cellerant Therapeutics Inc.
- 3.3.1. Overview
- 3.3.2. Financial Analysis
- 3.3.3. SWOT Analysis
- 3.3.4. Recent Developments
3.4. Kyowa Kirin Co. Ltd.
- 3.4.1. Overview
- 3.4.2. Financial Analysis
- 3.4.3. SWOT Analysis
- 3.4.4. Recent Developments
3.5. Mylan Pharmaceutical Pvt. Ltd.
- 3.5.1. Overview
- 3.5.2. Financial Analysis
- 3.5.3. SWOT Analysis
- 3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players

4. Market Segmentation

4.1. Global Chemotherapy-Induced Neutropenia Treatment Market by Therapy Type
- 4.1.1. Antibiotic Therapy
- 4.1.2. Colony-Stimulating Factor Therapy
- 4.1.3. Granulocyte Transfusion
- 4.1.4. Splenectomy Procedure
- 4.1.5. Others
4.2. Global Chemotherapy-Induced Neutropenia Treatment Market by Distribution Channel
- 4.2.1. Hospital Pharmacy
- 4.2.2. Retail Pharmacy
- 4.2.3. Online Pharmacy

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. Novartis AG
6.2. Partner Therapeutics Inc.
6.3. Pfizer Inc.
6.4. Spectrum Pharmaceuticals Inc.
6.5. Teva Pharmaceutical Industries Ltd.
6.6. Coherus Biosciences Inc.